tried and failed before celecoxib was used; • a therapeutic buy-up program, in which a maximum allowable cost is implemented with the member paying the difference; or • a three-tiered copayment plan, in which celecoxib is placed in the highest tier with other nonformulary medications.
and the actual amount paid was determined, and a percentage of savings was calculated. The therapeutic buy-up program saves this plan 36.7% over what the plan would have paid if no restrictions were implemented.
Claims data were examined from a 46,000-member group that uses a prior-authorization program to control the use of celecoxib. In this type of program, pharmacists are trained in specific disease states and their appropriate treatments. They are responsible for determining whether celecoxib is being prescribed appropriately according to guidelines set by the plan, and approve or deny submitted claims accordingly. 3 The prior-authorization requirements do not specify a diagnosis; however, they do outline specific screening criteria for patients who should not be on NSAIDs, based on factors such as increased age, risk of GI bleeding, use of anticoagulants, and previous intolerance to other NSAIDs. Data for appeals were not available or tracked by API.
Under this plan, celecoxib may be used by patients who: • are older than 65; A comparison was made between celecoxib claims that were paid and those claims that were submitted but denied payment. The cost per unit of therapy (capsule) was calculated by dividing the total amount paid by the plan by the total number of capsules dispensed. A listing of all celecoxib claims that were ultimately rejected was obtained, and the total number of capsules that were not dispensed was also calculated. Using the cost per capsule, cost savings were determined. The cost savings were then compared with the potential total amount paid (paid claims plus rejected claims). The total savings was 49.8%.
The final group studied is a plan with 13,000 lives that has implemented a step-therapy program.
Step therapy is similar to prior authorization; predetermined requirements are established and the computer system will automatically pay the submitted claim if, within the previous 90 days, the patient has used at least one of the following for 30 days: • Cox II inhibitor or NSAID; • H2 antagonist, proton pump inhibitor, Cytotec (prostaglandin), sucralfate;
• anticoagulant/antiplatelet therapy; or • 10 days of combination ulcer treatment (i.e., PrevPac).
As with prior authorization, a comparison was made between all paid celecoxib claims and all celecoxib claims that were submitted but denied payment. A total for all submitted celecoxib claims, regardless of final payment status, was determined. The percentage of savings was calculated to be 74.1%.
Step therapy is the program that realizes the largest percentage in cost savings of the plans examined (see Table 1 , above).
nn Limitations
Certain inherent limitations and assumptions must be addressed concerning this analysis and the methods used. Ideally, data for such an analysis would be collected over a two-year period. Celecoxib was released during the first quarter of 1999; therefore, only several months' (February-December 1999) worth of data could be examined.
The software used to obtain claims data, Apothequery, has two main limitations that must be considered. First, integration of the program with other software is difficult, and at the time this article was written, the database was updated only every 30 days. The software used to manipulate and examine the data is limited in the number of records it will hold at one time, lead- ing to additional steps in the data-examination process. Such piecemeal examination of the data allows for an increased margin of error in calculations. A fairly thorough knowledge of the syntax of the software is necessary in order to perform the necessary statistical manipulations of the data. Assumptions were made that the data received were accurate and correct, and that celecoxib was being prescribed correctly (i.e., for indications discussed previously, and not for chronic pain). Administrative fees and transmission costs were not included due to their variability from plan to plan. Differences in demographics among patient populations were not considered. The focus of this study was to determine which benefit design was the most cost-effective; however, because of the lack of availability of diagnostic information, cost differences between dosages had to be omitted.
Benefit Strategy Comparisons
Certain biases must be addressed from the perspective of the PBM. These companies, like any other for-profit organizations, must make money in order to succeed. PBMs are faced with the challenge of reducing drug costs for their clients while maintaining a high standard of care for their clients' members. PBMs must negotiate with pharmaceutical manufacturers to keep medication costs as low as possible, while keeping the patient's best interest as their top priority.
Step therapy shows the biggest cost savings to a plan; however, the actual amount of this savings may be over-inflated because of the small size of the plan used as an example.
nn
Conclusion
Since its release in early 1999, celecoxib has become one of the most widely prescribed drugs for arthritis, and has since been awarded the additional indication of familial adenomatous polyposis. Celecoxib was the first member of the new class of drugs known as Cox II inhibitors, and was marketed as a drug that would reduce GI effects that other NSAIDs cause. Many PBMs and health benefit plans have addressed the high cost and potential for misuse of celecoxib and have placed restrictions on its use by implementing various methods of control. Despite the limitations mentioned, it can be concluded that step therapy provides a plan the greatest amount of cost avoidance because it is the most restrictive of the cost savings measures examined.
